Meeting
2017 Gastrointestinal Cancers Symposium
The treatment continuum of panitumumab, cetuximab, and bevacizumab in 1st through 3rd line by KRAS, NRAS, and BRAF mutation status among mCRC patients treated at community cancer centers in the United States.
Authors
Kimberly Lowe
Amgen, Seattle, WA
Kimberly Lowe , Kristina Hool , George Kafatos , Michael Anthony Kelsh , Tamer Garawin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 638)
DOI
10.1200/JCO.2017.35.4_suppl.638
Abstract #
638
Poster Bd #
F12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
First Author: Ramya Thota
Poster
2016 Gastrointestinal Cancers Symposium
Assessment of treatment with panitumumab, cetuximab, and bevacizumab among mCRC patients with wild-type RAS or BRAF treated at community cancer centers in the United States.
First Author: Kimberly Lowe
Poster
2014 Gastrointestinal Cancers Symposium
Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer: Analysis of a large international cohort of 5,900 patients.
First Author: Gargi Dan Basu
Poster
2014 ASCO Annual Meeting
Analysis of progression-free survival in the new EPOC study in an “all wild-type” population.
First Author: John A. Bridgewater